DK541889D0 - Virus-modificerede tumorvacciner til immunterapi af tumormetastaser - Google Patents

Virus-modificerede tumorvacciner til immunterapi af tumormetastaser

Info

Publication number
DK541889D0
DK541889D0 DK541889A DK541889A DK541889D0 DK 541889 D0 DK541889 D0 DK 541889D0 DK 541889 A DK541889 A DK 541889A DK 541889 A DK541889 A DK 541889A DK 541889 D0 DK541889 D0 DK 541889D0
Authority
DK
Denmark
Prior art keywords
pct
virus
tumor
immunery
modified
Prior art date
Application number
DK541889A
Other languages
Danish (da)
English (en)
Other versions
DK541889A (da
Inventor
Volker Schirrmacher
Original Assignee
Deutsches Krebsforsch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6348527&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK541889(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Deutsches Krebsforsch filed Critical Deutsches Krebsforsch
Publication of DK541889A publication Critical patent/DK541889A/da
Publication of DK541889D0 publication Critical patent/DK541889D0/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK541889A 1988-03-01 1989-10-31 Virus-modificerede tumorvacciner til immunterapi af tumormetastaser DK541889D0 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3806565A DE3806565A1 (de) 1988-03-01 1988-03-01 Virusmodifizierte tumorvakzinen fuer die immuntherapie von tumormetastasen
PCT/EP1989/000186 WO1989007946A1 (fr) 1988-03-01 1989-02-27 Vaccins tumoraux modifies viralement pour immunotherapie de metastases tumorales

Publications (2)

Publication Number Publication Date
DK541889A DK541889A (da) 1989-10-31
DK541889D0 true DK541889D0 (da) 1989-10-31

Family

ID=6348527

Family Applications (1)

Application Number Title Priority Date Filing Date
DK541889A DK541889D0 (da) 1988-03-01 1989-10-31 Virus-modificerede tumorvacciner til immunterapi af tumormetastaser

Country Status (10)

Country Link
US (1) US5273745A (enExample)
EP (1) EP0331102B1 (enExample)
JP (1) JPH02504034A (enExample)
KR (1) KR900700130A (enExample)
AT (1) ATE90877T1 (enExample)
AU (1) AU3188989A (enExample)
DE (2) DE3806565A1 (enExample)
DK (1) DK541889D0 (enExample)
ES (1) ES2042828T3 (enExample)
WO (1) WO1989007946A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3922444A1 (de) * 1988-03-01 1991-01-10 Deutsches Krebsforsch Virusmodifizierte tumorvakzine fuer die immuntherapie von tumormetastasen
DE4204132C2 (de) * 1991-02-12 1997-12-18 Rudolf Dr Pekar Aufbereitung für die Gewinnung von Vakzinen für eine Immuntherapie
EP0607309B1 (en) * 1991-10-04 2003-01-08 Whitehead Institute For Biomedical Research The regulation of systemic immune responses utilizing cytokines and antigens
ES2315595T3 (es) * 1993-04-30 2009-04-01 Wellstat Biologics Corporation Composiciones para tratar cancer con uso de virus.
DE19506483A1 (de) * 1995-02-24 1996-08-29 Jens Dr Dr Atzpodien Lyophilisat-Vakzine
US6406689B1 (en) 1995-10-03 2002-06-18 Frank W. Falkenberg Compositions and methods for treatment of tumors and metastatic diseases
EP0805207A1 (en) * 1996-05-02 1997-11-05 Gesellschaft für Biotechnologische Forschung mbH (GBF) Polycistronic expression plasmid for tumor rejection
ATE245163T1 (de) * 1996-05-03 2003-08-15 Univ Jefferson Impfstoff gegen metastasierenden kolorektalkrebs.
PL328790A1 (en) * 1996-10-04 1999-02-15 Univ Jefferson T-lymphocytes provoking an immunological response and methods of using them
DE69731950T2 (de) * 1997-08-22 2005-05-19 Science Park Raf S.P.A. Tumorvakzinierung mittels Verwendung autologer oder HLA-verwandter Antigen präsentierender Zellen (APC), die mit einem Tumorantigen sowie einem eine Immunantwort hervorrufenden Fremdantigen transduziert sind
TW575420B (en) * 1997-09-22 2004-02-11 Kirin Brewery Composition for enhancing cellular immunogenicity comprising alpha-glycosylceramides
US7780962B2 (en) * 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US20030044384A1 (en) * 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
JP2003530301A (ja) * 1999-04-15 2003-10-14 ウェルスタット バイオロジクス コーポレイション ウイルスを用いた新生物の処置
US8147822B1 (en) 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
EP1092439A1 (en) * 1999-10-13 2001-04-18 Thorsten Dr. Ahlert Activation of antigen-specific T cells by virus/antigen-treated dendritic cells
RU2172182C1 (ru) * 2000-07-27 2001-08-20 Бритов Василий Александрович Способ профилактики и лечения заболеваний иммунной системы и средство для его осуществления
KR20040094635A (ko) * 2003-05-02 2004-11-10 주식회사 엠디바이오알파 항종양 활성의 유도를 위한 종양 백신의 제조방법 및그것을 함유하고 있는 약제 조성물
WO2007064802A1 (en) 2005-12-02 2007-06-07 The Mount Sinai Medical Center Of New York University Chimeric viruses presenting non-native surface proteins and uses thereof
US9283266B2 (en) * 2008-02-28 2016-03-15 University Of Notre Dame Metastasis inhibition preparations and methods
CN102149820B (zh) 2008-09-12 2014-07-23 国立大学法人三重大学 能够表达外源gitr配体的细胞
US20110206736A1 (en) * 2008-09-23 2011-08-25 Thomas Jefferson University Cancer Vaccines Against Mucosal Antigens and Methods of Making and Using the Same
EP2327764B1 (en) 2009-11-30 2011-12-28 United Cancer Research Institute New clone of Newcastle disease virus, its manufacture and its application in the medical treatment of cancer
GEP20196976B (en) 2013-03-14 2019-06-10 Sloan Kettering Cancer Center Memorial Newcastle disease viruses and uses thereof
CN107073099B (zh) 2014-02-27 2022-09-27 默沙东公司 用于治疗癌症的联合方法
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
WO2020037215A1 (en) 2018-08-17 2020-02-20 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2918927A1 (de) * 1979-05-10 1980-11-20 Hans Prof Dr Limburg Arzneipraeparat zur behandlung von carcinomen und verfahren zu dessen herstellung
DE3432714A1 (de) * 1984-09-06 1986-04-24 Behringwerke Ag, 3550 Marburg Tumortherapeutikum und verfahren zu seiner herstellung
HU197517B (en) * 1984-07-30 1989-04-28 Laszlo Csatary Process for production of terapeutical composition applicable against virus infection

Also Published As

Publication number Publication date
WO1989007946A1 (fr) 1989-09-08
ATE90877T1 (de) 1993-07-15
EP0331102B1 (de) 1993-06-23
DK541889A (da) 1989-10-31
KR900700130A (ko) 1990-08-11
DE58904760D1 (de) 1993-07-29
JPH02504034A (ja) 1990-11-22
ES2042828T3 (es) 1993-12-16
US5273745A (en) 1993-12-28
AU3188989A (en) 1989-09-22
DE3806565C2 (enExample) 1991-04-25
DE3806565A1 (de) 1989-09-14
EP0331102A1 (de) 1989-09-06

Similar Documents

Publication Publication Date Title
DK541889A (da) Virus-modificerede tumorvacciner til immunterapi af tumormetastaser
ATE149841T1 (de) Impfstoffe gegen krebs und infektionskrankheiten
ATE105334T1 (de) Schimaerische glykoproteine enthaltende immunogenische abschnitte von menschlichem parainfluenzavirus typ 3.
DK1021547T3 (da) Vaccineformuleringer indeholdende papillomviruskapsomer og fremgangsmåder til anvendelse heraf
ATE295895T1 (de) Genetischer impfstoff gegen den immunschwäche virus
DK157087A (da) Multivalent vaccine, isaer herpesvirusvaccine, dens anvendelse og deri indgaaende virus
ATE391726T1 (de) Modifiziertes gp100 und dessen verwendung
ATE402713T1 (de) Genetisch manipulierte herpesviren zur behandlung von tumoren
FI823021A7 (fi) Tuotteet, jotka osoittavat hepatitis B virus e antigeenin antigeenisuuden ja menetelmät näiden antigeenien vavalmistamiseksi.
BR9704879A (pt) Composição de vacina e uso de um vírus cav vivo
ATE101200T1 (de) Impfstoffe gegen menschliche respiratorische viren.
DK0889969T3 (da) Rekombinante adenovirale til genterapi af humane tumorer
ES553425A0 (es) Perfeccionamientos en la fabricacion de conjugados de proteinas portadores de antigenos inmunogenicos para vacunas contra la malaria
AR015237A1 (es) Una composicion de membranas celulares tumorales modificadas con hapteno, metodo para obtenerlas y su uso.
DE69333730D1 (de) Impfstoff, der acemannan als adjuvans enthält
BR9603227A (pt) Vírus ndv da cepa c2 vacina para uso na proteção de aves omésticas contra doença de newcastle (nd) processos para a preparação de vírus para preparação de uma vacina e para controlar doença de newcastle em aves domésticas
BR9306187A (pt) Vacina bacterin-toxóide pasteurella haemolytica tipo a-1
ES550089A0 (es) Procedimiento para producir una vacuna coadyuvada que contiene un antigeno seleccionado de proteinas, bacterias y virus.
KR890006254A (ko) 비-특이적 면역성 인듀서의 제조방법
DK41885A (da) 987p-fimbrie-producerende mikroorganisme, vaccine til immunisering af grise samt fremgangsmaade til fremstilling af vaccinen
DE68920345D1 (de) Lebendes Kombinationsvakzin.
DK0485463T3 (da) Svækket hundeparvovirus (CPV), vaccine omfattende CPV og fremgangsmåde til forebyggelse af CPV-infektion i hunde
NL300073I1 (nl) Vaccin.
SE8700466D0 (sv) Vaccines against melanoma
ATE166880T1 (de) Impfstoff gegen cholera

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment